Stereotaxis, Inc. (STXS)
Market Cap | 144.09M |
Revenue (ttm) | 28.15M |
Net Income (ttm) | -19.64M |
Shares Out | 75.05M |
EPS (ttm) | -0.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 102,811 |
Open | 1.90 |
Previous Close | 1.87 |
Day's Range | 1.87 - 1.94 |
52-Week Range | 1.55 - 3.81 |
Beta | 1.70 |
Analysts | Buy |
Price Target | 5.61 (+190.67%) |
Earnings Date | May 9, 2023 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to ma... [Read more]
Financial Performance
In 2022, Stereotaxis's revenue was $28.15 million, a decrease of -19.63% compared to the previous year's $35.02 million. Losses were -$19.64 million, 62.8% more than in 2021.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for STXS stock is "Buy." The 12-month stock price forecast is $5.61, which is an increase of 190.67% from the latest price.
News

Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening...

Stereotaxis Inc. (STXS) Reports Q4 Loss, Misses Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 23.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Reports 2022 Full Year Financial Results
ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

Stereotaxis to Present at Cowen 43rd Annual Health Care Conference
ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
ST. LOUIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis' Genesis System
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of p...

Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference
ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Reports 2022 Third Quarter Financial Results
ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

Stereotaxis to Report Third Quarter Financial Results on November 10, 2022
ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

Stereotaxis Receives St. Louis Mayor's Innovation Award for 2022
ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded...

International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value
ST. LOUIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendanc...

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System
ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland...

Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 19.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Reports 2022 Second Quarter Financial Results
ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline
ST. LOUIS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significan...

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022
ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter
ST. LOUIS, July 11, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark su...

Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP
16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders 16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation f...

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Reports 2022 First Quarter Financial Results
ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures
Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology Denmark's only robot...

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders
Stereotaxis robotic technology now in use in 25 countries Stereotaxis robotic technology now in use in 25 countries

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis
Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use s...

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?